PCOS, a condition impacting millions of women worldwide, gets a new name
PCOS a condition impacting millions of women – A health issue affecting women’s fertility and diabetes risk remains underdiagnosed in numerous instances, yet experts believe renaming it could improve care for more patients. While the term Polycystic Ovarian Syndrome (PCOS) suggests ovarian cysts, the disorder encompasses a wider range of symptoms, including irregular menstrual cycles, reproductive challenges, female-patterned baldness, type 2 diabetes, and cardiovascular disease, according to the World Health Organization (WHO). The Lancet paper, published Tuesday, marks a significant shift in how the condition is classified, introducing a new designation: Polyendocrine Metabolic Ovarian Syndrome (PMOS).
The Scope of the Condition
Estimates from the WHO indicate that 10% to 13% of women of reproductive age globally are impacted by PCOS. However, approximately 70% of these individuals remain unaware of their diagnosis, highlighting the need for clearer terminology. Dr. Helena Teede, an endocrinologist and professor of Women’s Health at Monash University in Australia, emphasized that the name’s lack of descriptive accuracy has contributed to misunderstandings, leading to missed diagnoses and suboptimal treatment approaches. Over her 25-year career, Teede has observed how the narrow focus on ovarian cysts has overshadowed the condition’s broader implications.
Why the Name Change Matters
The renaming aims to better reflect the condition’s multifaceted nature, as noted by the lead authors of the Lancet paper. This new designation, PMOS, underscores its role as a complex metabolic disorder with systemic effects. “By calling this condition polycystic ovary, we’re missing the big picture,” remarked Dr. Alla Vash-Margita, an associate professor at Yale University and division chief for pediatric adolescent gynecology at the Yale School of Medicine. She added that the old name perpetuated stigma, with many assuming patients have visible ovarian cysts, which is not always the case.
Evolution of Medical Understanding
Dr. Andrea Dunaif, a professor at the Icahn School of Medicine at Mount Sinai in New York, described the syndrome’s initial classification as a reproductive disorder. Early research linked it to elevated male hormone levels, which can disrupt menstrual regularity and fertility. By the 1980s, scientists discovered its connection to insulin resistance, a condition where the body fails to respond to insulin, forcing it to produce more to maintain normal function. This metabolic component has since been identified as a critical factor in the development of diabetes and other systemic issues.
Since then, studies have revealed that PMOS is not limited to reproductive health but also influences metabolic processes, increasing risks for liver and heart disease. More recent findings have expanded the list of associated conditions, including sleep apnea, mental health disorders like depression and anxiety, and body dysmorphia. These developments have prompted researchers to advocate for a name that captures the full spectrum of the condition’s impact.
The New Name: A Broader Perspective
Teede explained that the term polyendocrine in PMOS better aligns with the syndrome’s endocrine-related nature. “People with PMOS experience a disruption in the body’s chemical messenger system, which can lead to widespread effects,” she stated. This clarification is crucial, as it shifts the focus from localized ovarian issues to a more holistic view of the condition. Vash-Margita echoed this sentiment, noting that the new name reflects the interconnectedness of metabolic and endocrine functions.
A Collaborative Effort Spanning Years
The transition from PCOS to PMOS has been a 14-year journey involving global collaboration. According to the Lancet paper, 56 patient and professional organizations contributed to the rebranding process, ensuring a broad consensus on the terminology. Rachel Morman, Chair of Verity PCOS UK, highlighted the potential impact of the name change: “This shift will reframe the conversation and demand that it is taken as seriously as the long-term, complex health condition it is.”
Despite the progress, some experts remain cautious. Dunaif pointed out that while the new name captures more of the condition’s metabolic aspects, it may still benefit from further subtyping to account for varying manifestations. For example, she noted that family histories suggest individuals without ovaries could also exhibit metabolic complications, indicating the syndrome’s reach extends beyond the reproductive system. “The name might be more accurate if it categorized symptoms for those experiencing primarily reproductive issues versus those with metabolic challenges,” she suggested.
Implications for Multidisciplinary Care
Teede argued that the revised name will encourage collaboration across medical specialties, as PMOS affects multiple body systems. While gynecologists have traditionally taken the condition seriously, its metabolic and hormonal components require input from endocrinologists, cardiologists, and mental health professionals. This interdisciplinary approach is essential for addressing the syndrome’s diverse symptoms effectively. “The condition’s impact is not confined to one area of health, so all kinds of medical specialties should be more aware,” Teede emphasized.
The Lancet paper also underscored the importance of reducing stigma associated with the old name. “There was a lot of myth and misunderstanding, with people thinking they had large ovarian cysts when they didn’t,” Vash-Margita said. She stressed that the new name could foster greater awareness, prompting earlier interventions and more targeted treatments. “The hope is that a new name will help give the condition the attention it deserves,” Dunaif added, while acknowledging that the term still has room for refinement.
As the medical community embraces PMOS, the focus is shifting from symptom management to a comprehensive understanding of the disorder’s role in long-term health. The renaming reflects not only scientific advancements but also a commitment to redefining how the condition is perceived and addressed. With continued research and collaboration, the new term aims to bridge the gap between diagnosis and holistic care, ensuring that millions of women receive the support they need.
Metabolic Syndrome and Its Broader Impact
Additional research has drawn connections between PMOS and other metabolic conditions, such as early dementia. A recent study suggests that metabolic syndrome, a cluster of risk factors including high blood pressure and insulin resistance, significantly increases the likelihood of developing cognitive decline. This link reinforces the idea that PMOS is not just a reproductive disorder but also a critical player in systemic health. “What you do makes a difference,” the study noted, emphasizing the importance of lifestyle interventions in mitigating long-term risks.
By expanding the terminology to PMOS, the medical field seeks to align the condition with its growing complexity. The new name is expected to spark renewed interest in understanding and managing its various effects, from reproductive health to metabolic and neurological concerns. As experts continue to refine their approach, the goal remains clear: to ensure that patients receive the comprehensive care they need, no longer constrained by a name that only partially describes the syndrome’s reach.
